Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled trial of oral olinciguat in stable sickle cell disease
2019-001899-11Phase 2Terminated
- Sponsor
- Cyclerion Therapeutics
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing Olinciguat once daily with Placebo once daily (2 arms). Primary endpoints: Safety and Pharmacodynamic effects. Started Aug 2019; status: terminated.
02
Drugs
olinciguat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2019-001899-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001899-11.